The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The prognosis of Diffuse Large B cell Lymphoma (DLBCL) patients with an early relapse is
dismal. Atezolizumab has shown promising activity in relapsed DLBCL patients. Toxicity data
on atezolizumab are available for > 6000 patients and is manageable. The assumption of this
study is that atezolizumab consolidation will result in higher disease free survival by
eradicating minimal residual disease In melanoma and lung cancer consolidation immunotherapy
after chemoradiotherapy has shown an increase in survival.
Phase:
Phase 2
Details
Lead Sponsor:
Stichting Hemato-Oncologie voor Volwassenen Nederland